<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="70636"><DrugName>MEDI-2338</DrugName><DrugSynonyms><Name><Value>interleukin 18-targeted monoclonal antibody (inflammation), MedImmune</Value></Name><Name><Value>anti-IL-18 mAb (inflammation), MedImmune</Value></Name><Name><Value>MEDI-2338</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18008">MedImmune LLC</CompanyOriginator><CompaniesSecondary><Company id="18008">MedImmune LLC</Company></CompaniesSecondary><CrossReferences><SourceEntity id="70636" type="Drug"><TargetEntity id="733375" type="siDrug">MEDI-2338</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4813" type="Action"><TargetEntity id="1562" type="Mechanism">Anti-IL-18</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="188">Inflammatory disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="4813">IL-18 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1470">Respiratory system agent</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="51">Monoclonal antibody</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>R</Code><Name>RESPIRATORY SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-17T10:54:18.000Z</LastModificationDate><ChangeDateLast>2013-04-18T00:00:00.000Z</ChangeDateLast><AddedDate>2011-03-25T12:19:17.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt; was developing MEDI-2338, an interleukin 18 (IL-18)-targeted monoclonal antibody,   for the potential iv treatment of  post-acute coronary syndrome (ACS) chronic obstructive pulmonary disease (COPD) [&lt;ulink linkID="1179246" linkType="Reference"&gt;1179246&lt;/ulink&gt;], [&lt;ulink linkID="1210721" linkType="Reference"&gt;1210721&lt;/ulink&gt;]. In March 2011, a phase I trial was initiated in South Africa and the UK; the study was completed in December 2011  [&lt;ulink linkID="1179246" linkType="Reference"&gt;1179246&lt;/ulink&gt;].  By June 2012, the program was no longer listed on   company pipelines [&lt;ulink linkID="1311095" linkType="Reference"&gt;1311095&lt;/ulink&gt;], [&lt;ulink linkID="1313681" linkType="Reference"&gt;1313681&lt;/ulink&gt;]. In April 2013, it was confirmed that the company was no longer pursuing this compound due to strategic reasons [&lt;ulink linkID="1405985" linkType="Reference"&gt;1405985&lt;/ulink&gt;] &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2011, a randomized, single-blind, phase I study (&lt;ulink linkID="75774" linkType="Protocol"&gt;NCT01322594&lt;/ulink&gt;; CD-RI-MEDI2338-1033; 2010-022879-54) was initiated in patients with mild to moderate COPD (expected n = 30) in South Africa and the UK, to assess the safety, pharmacokinetics and pharmacodynamics of MEDI-2338. The study was completed in December  2011  [&lt;ulink linkID="1179246" linkType="Reference"&gt;1179246&lt;/ulink&gt;].      In April 2013, data from the study were presented at the Ninth SMi Asthma and COPD conference in London, UK. The drug was well tolerated in the study [&lt;ulink linkID="1405985" linkType="Reference"&gt;1405985&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>2013-04-16T00:00:00.000Z</StatusDate><Source id="1405985" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2013-04-16T00:00:00.000Z</StatusDate><Source id="1405985" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2013-04-16T00:00:00.000Z</StatusDate><Source id="1405985" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2011-03-23T00:00:00.000Z</StatusDate><Source id="1179246" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2011-03-23T00:00:00.000Z</StatusDate><Source id="1179246" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2009-11-05T00:00:00.000Z</StatusDate><Source id="1055018" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1405985" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1405985" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1405985" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00999"><Name>IL-18 receptor</Name><SwissprotNumbers><Swissprot>Q13478</Swissprot><Swissprot>Q61098</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2302576" number="WO-2012085015" title="Anti-IL-18 antibodies and their uses"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>